Management of Mast Cell Disorders

Initial Pharmacologic Management

• The American College of Dermatology recommends H1 receptor antihistamines as first-line therapy to control dermatologic manifestations, tachycardia, and abdominal discomfort 1
• Both sedating and non-sedating H1 antihistamine options are effective for symptom control, with doses potentially needing to be 2-4 times FDA-approved levels 2, 3
• H2 receptor antihistamines should be added for persistent gastrointestinal symptoms, particularly for gastric hypersecretion and peptic ulcer disease 1, 2
• Combined H1 and H2 antihistamine therapy is effective for controlling severe pruritus and wheal formation when monotherapy fails 2

Second-Line Mast Cell Stabilizers

• Oral cromolyn sodium is effective for gastrointestinal symptoms, including diarrhea, abdominal pain, nausea, and vomiting, and may also help cutaneous symptoms and pruritus 1, 2
• Progressive introduction of oral cromolyn sodium reduces side effects such as headache, sleepiness, irritability, and abdominal pain 2

Additional Mediator-Blocking Agents

• Cyproheptadine is recommended for diarrhea and nausea 1
• Aspirin may reduce flushing and hypotensive episodes from prostaglandin D2 secretion, but must be introduced in a controlled clinical setting due to potential paradoxical mast cell activation 1
• Proton pump inhibitors should be used when H2 antihistamines fail to control gastrointestinal symptoms 2

Emergency Management

• Epinephrine must be administered intramuscularly in a recumbent position for hypotension, wheezing, laryngeal edema, cyanotic episodes, or recurrent anaphylactic attacks 2
• All patients with a history of systemic anaphylaxis must be prescribed epinephrine autoinjectors 1
• Systemic corticosteroids may help acute episodes but should be tapered quickly to limit adverse effects 1

Refractory and Severe Cases

• Omalizumab should be considered when MCAS is resistant to standard mediator-targeted therapies 1
• PUVA therapy has proven effective for bullous diffuse cutaneous mastocytosis, even with life-threatening mediator release episodes 2

Critical Implementation Considerations

• Medications must be introduced cautiously as some patients experience paradoxical reactions 1
• Medication trials should be conducted in controlled settings with emergency equipment available 1
• Temperature control and anxiety and stress avoidance are essential for decreasing symptoms and antihistamine requirements 1, 2
• Careful trigger identification and avoidance is crucial alongside pharmacologic interventions 1

Patient and Caregiver Education

• Education of parents and care providers is essential for pediatric cases 2
• Community communication protects children and prevents life-threatening episodes during surgery, imaging procedures with dyes, and dental work 2
• It is essential to clarify that cutaneous mastocytosis is not contagious 2

Treatment Algorithm by Severity

• For mild symptoms, start H1 antihistamines alone 1
• For moderate symptoms, add H2 antihistamines and consider cromolyn sodium for GI symptoms 1, 2
• For persistent symptoms, add leukotriene antagonists, and consider aspirin in a controlled setting 1
• For refractory symptoms, consider omalizumab, systemic corticosteroids (short-term), or PUVA therapy 1, 2

Management of Mast Cell Disorder with Recurrent Symptomatic Episodes

First-Line Pharmacologic Management

• The American Academy of Allergy, Asthma, and Immunology recommends starting with dual H1 and H2 antihistamine therapy at high doses, adding oral cromolyn sodium for gastrointestinal symptoms, and prescribing epinephrine autoinjectors for emergency use in patients with mast cell disorders 4
• Second-generation H1 antihistamines, such as cetirizine or fexofenadine, work prophylactically to control symptoms like palpitations, dizziness, and acid reflux, and should be used instead of first-generation H1 antihistamines due to their lower risk of sedation, impaired driving ability, and cognitive decline 4

Additional Mediator-Blocking Agents for Specific Symptoms

• The American College of Allergy, Asthma, and Immunology suggests considering cyproheptadine for refractory diarrhea and nausea, as it functions as both an H1 antihistamine and serotonin receptor antagonist 4
• Montelukast or zileuton may be added for persistent symptoms, particularly if urinary leukotriene E4 levels are elevated, as they can reduce gastrointestinal symptoms and are useful when standard antihistamine therapy is insufficient 4

Emergency Management Protocol

• The American Heart Association recommends that patients with mast cell disorders and systemic symptoms, such as palpitations and dizziness, be prescribed epinephrine autoinjectors to carry at all times, and to use them immediately for severe reactions involving hypotension, respiratory distress, or laryngeal angioedema 4
• Assuming a supine position immediately at symptom onset can help prevent hypotensive episodes, and using a bedpan for diarrhea and an emesis basin while maintaining supine positioning can also be beneficial 4

Refractory Case Management

• The American Academy of Allergy, Asthma, and Immunology recommends considering omalizumab for refractory symptoms despite maximal antimediator therapy, as it can prevent anaphylactic episodes and reduce emergency department visits in patients with mast cell activation syndrome, although systemic corticosteroids should be reserved for severe refractory symptoms and tapered quickly to limit adverse effects 4

Evidence‑Based Pharmacologic Management of Mast Cell Activation Syndrome (MCAS)

First‑Line Therapy

• High‑dose H1 and H2 antihistamines constitute the cornerstone of MCAS management, targeting mast‑cell mediator release and alleviating cutaneous, gastrointestinal, and neurological symptoms. 5

Second‑Line Therapies

• Leukotriene receptor antagonists (e.g., montelukast or zafirlukast) should be added when urinary LTE₄ levels are elevated, providing additional control of mast‑cell–derived leukotriene effects. 5

Severe / Refractory Management

• Omalizumab may be employed for patients with refractory MCAS who do not respond adequately to high‑dose antihistamines and leukotriene antagonists, offering targeted IgE‑mediated mast‑cell stabilization. 5

Overall Treatment Paradigm

• The therapeutic approach to MCAS is centered on blocking mast‑cell mediators (antihistamines, leukotriene antagonists) and stabilizing mast cells (e.g., cromolyn sodium, omalizumab); opioid antagonists such as naloxone have no role in stabilizing mast cells or treating MCAS. 5